WELIREG for certain patients with previously treated advanced clear cell RCC
WELIREG for patients with certain VHL disease–associated tumors
WELIREG is approved for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).
CNS = central nervous system; PD-1/L1 = programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1); pNET = pancreatic neuroendocrine tumors; RCC = renal cell carcinoma; VEGF-TKI = vascular endothelial growth factor tyrosine kinase inhibitor; VHL = von Hippel-Lindau.
Connect with a Merck Associate
Merck is committed to helping you get answers to your questions. Connect with a Merck Associate now. This service is for US health care professionals.
The Merck Access Program
For access, coverage, and dispensing information, visit The Merck Access Program.